Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP
AssigneesAthena Neurosciences, Inc., Eli Lilly and Company
InventorsPeter A. Seubert, Dale B. Schenk, Lawrence C. Fritz
Life of this patent
Estimating the term…
Abstract
Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.
Claims14
An antibody composition comprising antibody molecules that specifically recognize an amino-terminal fragment of .beta.APP which is cleaved at the amino-terminus of .beta.-amyloid peptide, but which antibody molecules do not specifically recognize a secreted fragment of .beta.APP whose sequence extends into the sequence of .beta.-amyloid peptide.
A hybridoma that produces antibody molecules that specifically recognize an amino-terminal fragment of .beta.APP which is cleaved at the amino-terminus of .beta.-amyloid peptide, but which antibody molecules do not specifically recognize a secreted fragment of .beta.APP whose sequence extends into the sequence of .beta.-amyloid peptide.
Dependencies are inferred from the claim text.